US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
Levi & Korsinsky Notifies Shareholders of GSK plc(GSK) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 15, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
FiercePharma1d
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Citadel takes $384.5 million short position in GSK - FT
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
FierceBiotech3d
GSK plans to move vaccine R&D group from Maryland to the Boston area
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...
FierceBiotech10d
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
Drug developer GSK leaving 635K sf life sciences lab near DC
Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...